Brief: ArgenX Shows Positive Vyvgart Results In Adapt Seron Study
25/08/2025 06:07
Aug 25 (Reuters) - argenx SE ARGX.BR: ANNOUNCES POSITIVE TOPLINE RESULTS FROM ADAPT SERON STUDY OF VYVGART IN PATIENTS WITH ACHR-AB SERONEGATIVE GMG SBLA TO BE SUBMITTED TO FDA BY END OF 2025 PLANS SBLA SUBMISSION TO EXPAND VYVGART LABEL Source text: ID:nGNE4gBCLW Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles